Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balovaptan for Malignant Cerebral Edema in Acute Ischemic Stroke
NCT05399550Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute ischemic stroke (AIS) comparing Balovaptan with Placebo (2 arms). Primary endpoint: Amount of midline shift (MLS) at 72 hours. Planned start Jun 2022; status: withdrawn.
02
Drugs
balovaptan
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT05399550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399550.